Welcome to our dedicated page for BIOGEN SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
BIOGEN INC. (symbol: BIIB) is the issuer of record for a Form 4 filing submitted to the SEC. Parini Michael reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. (BIIB) reported that Chief Legal Officer Michael Parini received a grant of 7,405 Restricted Stock Units on September 1, 2026. The RSUs represent an equivalent number of shares of common stock and were awarded at a stated price of $0.00 per unit as an equity compensation award.
The RSUs vest in three equal yearly installments, beginning on the first anniversary of the grant date, September 1, 2026, and carry an expiration date of September 1, 2029. Following this grant, Parini holds 7,405 RSUs directly. No Rule 10b5-1 trading plan is reported for this award.
BIOGEN INC. filed an initial statement of beneficial ownership for executive Michael Parini, who serves as Chief Legal Officer. The filing reports no equity transactions or specific share holdings and notes that a Power of Attorney authorizing filings is attached as an exhibit.
FMR LLC and Abigail P. Johnson report beneficial ownership of 18,294,523.51 shares of Biogen Inc. common stock, representing 12.4% of the class. FMR LLC has sole voting power over 16,623,432.57 shares and sole dispositive power over all 18,294,523.51 shares.
Abigail P. Johnson reports sole dispositive power over the same 18,294,523.51 shares, with no voting power. One or more other persons may receive dividends or sale proceeds from these shares, but no single such person holds more than five percent of Biogen’s outstanding common stock.
Biogen Inc. director Lloyd Minor reported selling a total of 1,186 shares of Biogen common stock in two open-market or private transactions. On 3 August 2026 he sold 593 shares at $203.34 per share, and on 4 August 2026 he sold 593 shares at $200.96 per share.
The trades involve non-derivative common stock held directly and are affirmed as having been executed under a Rule 10b5-1 trading plan.
Lloyd Minor reported a planned or recent sale of company common stock. The notice covers 593 shares of common stock held at Fidelity Brokerage Services, originally acquired through restricted stock vesting on 06/09/2026 as compensation from the issuer. The filing also lists a sale of 593 common shares on 08/03/2026 for an aggregate value of $120,580.62, with the shares traded on NASDAQ.
Biogen Inc. reported Q2 2026 total revenue of $2,736.0 million, up slightly from $2,645.5 million a year earlier. Product revenue was $1,916.4 million, revenue from anti‑CD20 programs $513.5 million, Alzheimer’s collaboration revenue $63.7 million, and contract manufacturing, royalty and other revenue $242.4 million. Total cost and expense increased to $2,603.6 million from $1,901.5 million, and net income fell to $97.5 million (diluted EPS $0.66) from $634.8 million (EPS $4.33). For the first half of 2026, revenue was $5,213.8 million and net income $417.0 million, versus $5,076.5 million and $875.3 million in 2025.
On May 14, 2026 Biogen completed the $5,410.1 million acquisition of Apellis Pharmaceuticals, paying $41.00 per share in cash plus contingent value rights of up to $4.00 per share tied to SYFOVRE net sales. The deal added completed‑technology intangibles of $4,630.0 million, inventory of $712.0 million and goodwill of $501.5 million, financed with cash, sale of marketable debt securities, a new $2.0 billion 2026 Term Loan and a $400.0 million revolver draw. As of June 30, 2026, cash and cash equivalents were $1,285.0 million, notes payable and term loan totaled $8,090.2 million, and intangible assets, net, were $13,516.4 million. Operating cash flow for the first half was $1,094.4 million. Biogen recorded $173.3 million in restructuring charges year‑to‑date, including about $153.2 million related to Apellis integration, alongside ongoing Fit for Growth cost‑saving measures.
Biogen Inc. reported second quarter 2026 total revenue of $2.736 billion, up 3% year-over-year (2% at constant currency), driven by its Growth Portfolio, which generated $1.06 billion of revenue and grew 24% year-over-year, offsetting declines in multiple sclerosis and biosimilars revenue.
GAAP profitability was sharply lower, with GAAP diluted EPS of $0.66 versus $4.33 a year ago, and Non-GAAP diluted EPS of $3.60 versus $5.47, reflecting higher cost of sales, increased R&D and SG&A, acquired IPR&D, restructuring, and Apellis-related charges. MS product revenue fell 13% to $963 million, while rare disease revenue rose 11% to $602 million. Newly acquired SYFOVRE and EMPAVELI contributed specialized immunology revenue and supported Growth Portfolio expansion.
Biogen updated 2026 guidance, now expecting total revenue to increase by a mid-single digit percentage and guiding Non-GAAP diluted EPS of $12.00–$13.00, down from prior $14.25–$15.25, due to approximately $3.00 of acquired IPR&D and milestone charges and about $0.85 of dilution from the Apellis acquisition. Underlying EPS guidance excluding these items was raised by $0.60 to $15.85–$16.85. Management reiterates expectations for Apellis to be accretive to Non-GAAP EPS in 2027 with at least $250 million of run-rate synergies exiting 2027.
Biogen Inc. is warning that special research and development charges will weigh on its earnings for the middle of 2026. For the second quarter of 2026, it expects acquired in-process research and development, upfront and milestone expense of about $164 million, which management estimates will reduce GAAP and non-GAAP net income by roughly $0.95 per diluted share.
For the third quarter of 2026, Biogen anticipates additional acquired in-process research and development, upfront and milestone expense of $290 million to $320 million, tied to potential milestones and transactions that have not yet closed. This third-quarter expense is expected to lower GAAP and non-GAAP net income by about $1.75 to $1.95 per diluted share. These costs arise from collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions.
BIOGEN INC. director William A. Hawkins reported an equity compensation award rather than an open-market trade. He acquired 1,505 shares of Common Stock at no cost under a grant classified as a “grant, award, or other acquisition.”
After this award, Hawkins directly holds 10,365 Common Stock shares. According to a footnote, the related restricted stock units vest on the earlier of the next annual meeting or the anniversary of the date of grant of June 9, 2026, tying this award to his ongoing board service.